Cardiac resynchronization therapy for patients with cardiac sarcoidosis
| Autor: | Yasuki Kihara, Akinori Sairaku, Haruki Hashimoto, Mayuho Maeda, Yukiko Nakano, Haruo Hirayama, Yukihiko Yoshida |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Sarcoidosis medicine.medical_treatment Cardiac resynchronization therapy Comorbidity 030204 cardiovascular system & hematology law.invention Cardiac Resynchronization Therapy 03 medical and health sciences Ventricular Dysfunction Left 0302 clinical medicine Japan law Risk Factors Physiology (medical) Internal medicine medicine Prevalence Humans cardiovascular diseases 030212 general & internal medicine Aged Heart Failure Ejection fraction Ventricular End-Systolic Volume business.industry Incidence (epidemiology) Middle Aged medicine.disease Implantable cardioverter-defibrillator Death Sudden Cardiac Treatment Outcome Heart failure cardiovascular system Cardiology Artificial cardiac pacemaker Female Cardiology and Cardiovascular Medicine business Cardiomyopathies |
| Zdroj: | Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 19(5) |
| ISSN: | 1532-2092 |
| Popis: | Aims Sarcoidosis with cardiac involvement is a rare pathological condition, and therefore cardiac resynchronization therapy (CRT) for patients with cardiac sarcoidosis is even further rare. We aimed to clarify the clinical features of patients with cardiac sarcoidosis who received CRT. Methods and results We retrospectively reviewed the clinical data on CRT at three cardiovascular centres to detect cardiac sarcoidosis patients. We identified 18 (8.9%) patients with cardiac sarcoidosis who met the inclusion criteria out of 202 with systolic heart failure who received CRT based on the guidelines. The majority of the patients were female [15 (83.3%)] and underwent an upgrade from a pacemaker or implantable cardioverter defibrillator [13 (72.2%)]. We found 1 (5.6%) cardiovascular death during the follow-up period (mean ± SD, 4.7 ± 3.0 years). Seven (38.9%) patients had a composite outcome of cardiovascular death or hospitalization from worsening heart failure within 5 years after the CRT. Twelve (66.7%) patients had a history of sustained ventricular arrhythmias or those occurring after the CRT. Among the overall patients, no significant improvement was found in either the end-systolic volume or left ventricular ejection fraction (LVEF) 6 months after the CRT. A worsening LVEF was, however, more likely to be seen in 5 (27.8%) patients with ventricular arrhythmias after the CRT than in those without (P = 0.04). An improved clinical composite score was seen in 10 (55.6%) patients. Conclusions Cardiac sarcoidosis patients receiving CRT may have poor LV reverse remodelling and a high incidence of ventricular arrhythmias. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|